What if you could watch CMT2A unfold inside a neuron? CMTA’s new partnership just made it possible, and the early findings are changing the game.
Allele-Specific Silencing of MFN2 to Treat Peripheral Neuropathy
With CMTA support of $300,000, CMTA Strategy To Accelerate Research (CMTA-STAR) Advisory Board member Bruce...
CMTA’s $300K Investment in CRISPR for CMT2A
The Charcot-Marie-Tooth Association (CMTA) is investing $300,000 in a groundbreaking gene editing research project at...
CMTA’s $300K Investment in CRISPR for CMT2A
CMTA announced a $300,000 CMTA-STAR investment supporting CRISPR-based gene editing research aimed at selectively silencing disease-causing MFN2 mutations in CMT2A.
CMTA Fuels Breakthrough Imaging Research to Address CMT2A’s Cellular Weakness
The Charcot-Marie-Tooth Association (CMTA) announces a $90,860 investment in a new imaging research project at...
CMTA Fuels Breakthrough Imaging Research to Address CMT2A’s Cellular Weakness
CMTA announced a $90,860 CMTA-STAR investment supporting advanced imaging research to examine how MFN2 mutations disrupt cellular transport in CMT2A.
Tiny Movers, Big Clues: Dr. Manor Uses AI to Shed Light on CMT2A
With CMTA support of $90,860, researchers led by Uri Manor, PhD, at the University of...
CMT2A Biomarkers and Natural History
With CMTA support of $572,055, researchers at the Inherited Neuropathy Consortium led by Michael E. Shy, MD, are working to track disease progression and identify biomarkers in CMT2A. By studying blood, skin biopsy, and MRI biomarkers alongside clinical assessments, this project aims to develop critical tools for future clinical trials and advance CMT2A research.
CMTA Seed Money Draws NIH Support for Type 2 Gene Editing, Neurofilament Projects
CMTA seed funding has helped secure additional NIH support for two CMT type 2 research projects focused on gene editing and neurofilament restoration. The NIH awards build on CMTA-funded pilot work and reflect the role of early philanthropic investment in advancing translational CMT research toward therapeutic development.
2A Biomarkers and Outcome Measures
With CMTA support of $572,055, an international team of researchers from the Inherited Neuropathy Consortium,...
